Abstract PD1-05: Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib st
暂无分享,去创建一个
P. Ward | L. Molinero | L. Emens | C. Falkson | S. Chui | V. Kaklamani | G. Vidal | E. Hamilton | J. Rotmensch | Yijin Li | Kushagra Gupta | M. Patre